2019 International Congress Archives - Page 150 of 217

Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh

M. Rosebraugh, P. Kym, W. Liu, M. Facheris, J. Benesh (North Chicago, IL, USA)
Pharmacokinetics of Accordion Pill™ Carbidopa/Levodopa Following Multiple Doses in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, M. Leinonen, N. Navon, J. Meckler, R. Gendreau (Sarasota, FL, USA)
Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease

G. Loewen, P. Lewitt, C. Olanow, K. Kieburtz, G. Liang, R. Jimenez, K. Olson, E. Roberts (San Diego, CA, USA)
Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

NAO. Kanzato (Okinawa, Japan)
Phenotypic segregation in kindred with a novel ANO3 variant

V. Carvalho, F. Correia, J. Martins, J. Massano, T. Temudo (Matosinhos, Portugal)
Phenotypic spectrum of Progressive Supranuclear Palsy in a Tunisian cohort

A. Nasri, A. Neji, I. Kacem, T. Lansari, S. Mrabet, A. Gargouri, M. Ben Djebara, R. Gouider (Tunis, Tunisia)
Phenotypic variability and extreme age of presentation of GCH1 gene mutation in dopa-responsive dystonia

F. Abu Ahmad, P. Ponger, M. Rotstein, A. Migirov Sandrovitz, N. Giladi, A. Orr-Urtreger, T. Gurevich, S. Ben-Shachar (Tel Aviv, Israel)
Phosphodiesterase 10A and cognition in Parkinson’s disease

Z. Chappell, G. Pagano, H. Wilson, F. Niccolini, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)
Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia

J. González-Fernández, E. Zucchet, P. Calap-Quintana, P. González Cabo, MD. Moltó Ruiz (València, Spain)
Physiotherapy in cervical dystonia with focus on clinical assessments on ICF

M. Steinboeck, H. Unger (Bad Aibling, Germany)